Despite its relatively low potency and short half-life, Compound 12 showed promising anti-tumour effectiveness and low side effects, indicating a great potential for developing or optimising WNK1 inhibitory compounds with enhanced bioavailability, stability, and potency to treat patients with AML and other cancers dependent on this pathway. The gene discussed is WNK1; the disease is cancer.